We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Exelixis (EXEL - Free Report) is expected to reveal quarterly earnings of $0.51 per share, indicating an increase of 54.6% compared to the year-ago period. Analysts forecast revenues of $562.88 million, representing an increase of 17.4% year over year.
Over the last 30 days, there has been an upward revision of 3.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Exelixis metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenues- Net product' of $505.98 million. The estimate indicates a change of +17.9% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Net product- CABOMETYX' reaching $501.25 million. The estimate suggests a change of +17.2% year over year.
According to the collective judgment of analysts, 'Revenues- License' should come in at $54.80 million. The estimate indicates a change of +21.2% from the prior-year quarter.
Analysts forecast 'Revenues- Collaboration services' to reach $1.94 million. The estimate points to a change of -61.9% from the year-ago quarter.
Exelixis shares have witnessed a change of -2.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.1% move. With a Zacks Rank #2 (Buy), EXEL is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about Exelixis (EXEL) Q4 Performance? Explore Wall Street Estimates for Key Metrics
The upcoming report from Exelixis (EXEL - Free Report) is expected to reveal quarterly earnings of $0.51 per share, indicating an increase of 54.6% compared to the year-ago period. Analysts forecast revenues of $562.88 million, representing an increase of 17.4% year over year.
Over the last 30 days, there has been an upward revision of 3.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Exelixis metrics that are routinely monitored and predicted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenues- Net product' of $505.98 million. The estimate indicates a change of +17.9% from the prior-year quarter.
Analysts' assessment points toward 'Revenues- Net product- CABOMETYX' reaching $501.25 million. The estimate suggests a change of +17.2% year over year.
According to the collective judgment of analysts, 'Revenues- License' should come in at $54.80 million. The estimate indicates a change of +21.2% from the prior-year quarter.
Analysts forecast 'Revenues- Collaboration services' to reach $1.94 million. The estimate points to a change of -61.9% from the year-ago quarter.
View all Key Company Metrics for Exelixis here>>>
Exelixis shares have witnessed a change of -2.8% in the past month, in contrast to the Zacks S&P 500 composite's +2.1% move. With a Zacks Rank #2 (Buy), EXEL is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>